pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

1,493 catalysts · 3,085 8k filing · 2,032 grant · 1,000 device adverse event · 910 approval · 674 device 510k · 583 earnings

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 56 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: approval×type: earnings×from 2026-01-29×clear all
type
  • 8k filing3,085
  • grant2,032
  • device adverse event1,000
  • approval910
  • device 510k674
  • earnings583
device pma
508
  • device recall215
  • phase 2 completion172
  • recall167
  • therapy area

    no tagged catalysts yet

    Week of Jan 26, 2026

    43
    ›Jan 29, 2026approval195d agoWEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 29, 2026approval195d agoWEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Jan 29, 2026approval195d agoRIZAFILM (RIZATRIPTAN BENZOATE) — FDA approvalNAL Pharmaceuticals Ltd

    Sponsor: GENSCO. Form: FILM. Route: ORAL

    full page →fda approvals ↗
    ›Jan 29, 2026approval195d agoSERTRALINE HYDROCHLORIDE — FDA approvalSERTRALINE HYDROCHLORIDE

    Sponsor: ZYDUS LIFESCIENCES. Form: CAPSULE. Route: ORAL

    full page →SERTRALINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 29, 2026approval195d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: RISING. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Jan 29, 2026approval195d agoRILPIVIRINE HYDROCHLORIDE — FDA approvalrilpivirine hydrochloride ODT

    Sponsor: SOMERSET THERAPS LLC. Form: TABLET. Route: ORAL

    full page →rilpivirine hydrochloride ODT →fda approvals ↗
    ›Jan 29, 2026approval195d agoLACOSAMIDE — FDA approvalAucta Pharmaceuticals Inc

    Sponsor: REGCON HOLDINGS. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Jan 29, 2026approval195d agoDIVALPROEX SODIUM — FDA approvaldivalproex sodium DR

    Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Jan 29, 2026approval195d agoDIVALPROEX SODIUM — FDA approvaldivalproex sodium DR

    Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Jan 29, 2026approval195d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: ACTAVIS ELIZABETH. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Jan 29, 2026approval195d agoXIMINO (MINOCYCLINE HYDROCHLORIDE) — FDA approvalOraPharma Inc

    Sponsor: JOURNEY. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 29, 2026approval195d agoLORBRENA (LORLATINIB) — FDA approvallorlatinib

    Sponsor: PFIZER. Form: TABLET. Route: ORAL

    full page →lorlatinib →fda approvals ↗
    ›Jan 29, 2026approval195d agoPRUCALOPRIDE SUCCINATE — FDA approvalPRUCALOPRIDE SUCCINATE

    Sponsor: ZYDUS LIFESCIENCES. Form: TABLET. Route: ORAL

    full page →PRUCALOPRIDE SUCCINATE →fda approvals ↗
    ›Jan 30, 2026approval194d agoZYPREXA ZYDIS (OLANZAPINE) — FDA approvalDR REDDYS LABORATORIES LTD

    Sponsor: CHEPLAPHARM. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoBRIVARACETAM — FDA approvalUCB SA

    Sponsor: SUNSHINE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoBRIVARACETAM — FDA approvalUCB SA

    Sponsor: SUNSHINE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoZYPREXA RELPREVV (OLANZAPINE PAMOATE) — FDA approvalCHEPLAPHARM Arzneimittel GmbH

    Sponsor: CHEPLAPHARM. Form: SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoAMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approvalUNASYN

    Sponsor: SANDOZ. Form: INJECTABLE. Route: INJECTION

    full page →UNASYN →fda approvals ↗
    ›Jan 30, 2026approval194d agoZYPREXA (OLANZAPINE) — FDA approvalTEVA PHARMACEUTICAL INDUSTRIES LTD

    Sponsor: CHEPLAPHARM. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoARSENIC TRIOXIDE — FDA approvalQuetzal Therapeutics LLC

    Sponsor: EUGIA PHARMA. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoEPIRUBICIN HYDROCHLORIDE — FDA approvalEPIRUBICIN HYDROCHLORIDE

    Sponsor: CIPLA LTD. Form: INJECTABLE. Route: INJECTION

    full page →EPIRUBICIN HYDROCHLORIDE →fda approvals ↗
    ›Jan 30, 2026approval194d agoAMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN) — FDA approvalHikma Pharmaceuticals Plc

    Sponsor: HIKMA PHARMS. Form: FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalEpic Pharma LLC

    Sponsor: PH HEALTH. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoLIVDELZI (SELADELPAR LYSINE) — FDA approvalseladelpar lysine

    Sponsor: GILEAD SCIENCES INC. Form: CAPSULE. Route: ORAL

    full page →seladelpar lysine →fda approvals ↗
    ›Jan 30, 2026approval194d agoLATANOPROST — FDA approvalXalatan

    Sponsor: EPIC PHARMA LLC. Form: SOLUTION/DROPS. Route: OPHTHALMIC

    full page →Xalatan →fda approvals ↗
    ›Jan 30, 2026approval194d agoLATANOPROST — FDA approvalXalatan

    Sponsor: EPIC PHARMA LLC. Form: SOLUTION/DROPS. Route: OPHTHALMIC

    full page →Xalatan →fda approvals ↗
    ›Jan 30, 2026approval194d agoLATANOPROST — FDA approvalXalatan

    Sponsor: EPIC PHARMA LLC. Form: SOLUTION/DROPS. Route: OPHTHALMIC

    full page →Xalatan →fda approvals ↗
    ›Jan 30, 2026approval194d agoEMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE (EMTRICITABINE) — FDA approvalemtricitabine

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →emtricitabine →fda approvals ↗
    ›Jan 30, 2026approval194d agoZYPREXA (OLANZAPINE) — FDA approvalTEVA PHARMACEUTICAL INDUSTRIES LTD

    Sponsor: CHEPLAPHARM. Form: POWDER. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoLAMOTRIGINE — FDA approvalLAMOTRIGINE

    Sponsor: ALEMBIC. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Jan 30, 2026approval194d agoLAMOTRIGINE — FDA approvalLAMOTRIGINE

    Sponsor: ALEMBIC. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Jan 30, 2026approval194d agoLAMOTRIGINE — FDA approvalLAMOTRIGINE

    Sponsor: ALEMBIC. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Jan 30, 2026approval194d agoLAMOTRIGINE — FDA approvalLAMOTRIGINE

    Sponsor: ALEMBIC. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Jan 30, 2026approval194d agoLAMOTRIGINE — FDA approvalLAMOTRIGINE

    Sponsor: ALEMBIC. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Jan 30, 2026approval194d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalEpic Pharma LLC

    Sponsor: TEVA PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoLYBALVI (OLANZAPINE) — FDA approval(olanzapine + samidorphan l-malate)

    Sponsor: ALKERMES INC. Form: TABLET. Route: ORAL

    full page →(olanzapine + samidorphan l-malate) →fda approvals ↗
    ›Jan 30, 2026approval194d agoVENLAFAXINE HYDROCHLORIDE — FDA approvalViatris Inc

    Sponsor: PLATINUM. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoCETIRIZINE HYDROCHLORIDE ALLERGY (CETIRIZINE HYDROCHLORIDE) — FDA approvalCETIRIZINE HYDROCHLORIDE

    Sponsor: BIONPHARMA. Form: CAPSULE. Route: ORAL

    full page →CETIRIZINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 30, 2026approval194d agoDAPTOMYCIN — FDA approvalDaptomycin Novo

    Sponsor: MEITHEAL. Form: POWDER. Route: INTRAVENOUS

    full page →Daptomycin Novo →fda approvals ↗
    ›Jan 30, 2026approval194d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalEpic Pharma LLC

    Sponsor: TEVA PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoENBREL (ETANERCEPT) — FDA approvalAMGEN INC

    Sponsor: IMMUNEX. Form: SYRINGE

    full page →fda approvals ↗
    ›Jan 30, 2026approval194d agoVALACYCLOVIR HYDROCHLORIDE — FDA approvalVALACYCLOVIR HYDROCHLORIDE

    Sponsor: JUBILANT GENERICS. Form: TABLET. Route: ORAL

    full page →VALACYCLOVIR HYDROCHLORIDE →fda approvals ↗

    Week of Feb 2, 2026

    7
    ›Feb 2, 2026approval191d agoCONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Feb 2, 2026approval
    ← prev
    page 1 of 30
    next →
    191d ago
    CONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Feb 2, 2026approval191d agoCONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Feb 2, 2026approval191d agoMETHYLENE BLUE — FDA approvalMETHYLENE BLUE

    Sponsor: ZYDUS LIFESCIENCES. Form: SOLUTION. Route: INTRAVENOUS

    full page →METHYLENE BLUE →fda approvals ↗
    ›Feb 2, 2026approval191d agoTYRUKO (NATALIZUMAB-SZTN) — FDA approvalnatalizumab biosimilar

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →natalizumab biosimilar →fda approvals ↗
    ›Feb 2, 2026approval191d agoLENALIDOMIDE — FDA approvalLENALIDOMIDE

    Sponsor: CIPLA. Form: CAPSULE. Route: ORAL

    full page →LENALIDOMIDE →fda approvals ↗
    ›Feb 2, 2026approval191d agoPRIMAQUINE (PRIMAQUINE PHOSPHATE) — FDA approvalprimaquine phosphate

    Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL

    full page →primaquine phosphate →fda approvals ↗
    $TEVA36.14+2.21%
    $RDY12.15-0.57%
    $PFE27.05+1.08%
    $TEVA36.14+2.21%
    $AMGN417.20+1.52%
    $GILD133.06-0.11%
    $VTRS16.28-0.91%
    $ALKS49.40+0.47%